Abstract
Acquired resistance to Hedgehog pathway inhibitors has been reported in the clinical setting and upregulation of noncanonical Hedgehog signaling is one of the major underlying mechanisms behind this resistance. As demonstrated in our recent study, greater clinical efficacy might be achieved by focusing on downstream targets of the chemokine-activated noncanonical Hedgehog signaling pathway such as BCAR4 and phospho-GLI2 (Ser149).
Original language | English (US) |
---|---|
Article number | e998900 |
Journal | Molecular and Cellular Oncology |
Volume | 2 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2 2015 |
Keywords
- BCAR4
- Hedgehog Gli2
- Long non-coding RNA
- breast cancer
- cancer treatment
- locked nucleic acid
- lung metastasis
- signaling pathway
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research